Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Qu... (accompanying table entitled Reconciliat...)

HOME >> MEDICINE >> NEWS

Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008

Date:11/3/2009

accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Income."

"Delivering another quarter of strong financial performance points to our success in building Nexavar as an oncology blockbuster and demonstrates our commitment to executing on our strategic priorities," said N. Anthony Coles, M.D., president and chief executive officer of Onyx. "As the next step in our plans to grow the company strategically, we recently announced our intention to acquire Proteolix Inc., a leader in the science of proteasome inhibition. Through continued investigation of Nexavar in a broad array of additional tumor types and investment in a growing number of pipeline candidates, we are creating multiple opportunities for additional value creation."

Revenue from Collaboration Agreement

For the third quarter 2009, Onyx reported revenue from its Nexavar collaboration agreement of $69.1 million compared to $50.8 million for the same period in 2008. The 36% increase in revenue from collaboration agreement between periods resulted from an increase in Nexavar sales and royalty revenue and a decrease in Nexavar commercial expenses.

Operating Expenses

Onyx recorded research and development expenses of $35.6 million in the third quarter 2009, compared to $21.8 million for the same period in 2008. Higher research and development expenses in the third quarter 2009 were primarily due to planned increases in the development program for Nexavar across additional tumor types, such as thyroid, colorectal and adjuvant liver cancer and Onyx's costs to further develop ONX 0801, including a milestone payment of $7.0 million to BTG International Limited. Selling, general and administrative expenses were $23.4 million in the third quarter 2009, compared to $19.3 million for the same period in 2008. Higher selling, general and administrative expenses were primarily due to headcount-related expenses to support Onyx's growth.
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
2. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
3. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
4. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
5. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
6. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
7. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
8. DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America
9. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
10. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
11. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference

Post Your Comments:

(Date:12/15/2009)... Interactive education program will train advocates to be ... Project developed with support from experts in ... ,, WASHINGTON, Dec. 15 ... they are accepting applications for the first-ever "Malaria ... train and educate participants to become leaders in ...

(Date:12/15/2009)... The following are the remarks by ... criminal division, at the Medicare Fraud Strike Force ... thank you for the enormous effort everyone at ... ,, Together, our Departments have and will continue ... made tremendous progress in fighting Medicare fraud in ...

(Date:12/15/2009)... study links chronic obstructive pulmonary disease, or COPD, with ... activate the body,s immune system. , The University ... awareness of the immune system,s role in COPD, a ... million Americans with wheezing, shortness of breath, chest tightening ... doctors are to find better ways to detect and ...

(Date:12/15/2009)... early to say that phthalates actually cause ... (HealthDay News) -- Common chemicals found in plastic ... growth of breasts in boys, preliminary research suggests. ... medical journal for pediatricians, adds fuel to the ... has been questioned by some scientists. The chemical ...

(Date:12/15/2009)... surgical method, with fewer complications, analysis finds, , , TUESDAY, ... diagnosing breast cancer, women and their doctors have some ... "core needle biopsy" procedure is nearly as effective in ... with fewer complications than the surgical version. , The ... issue of Annals of Internal Medicine , looked ...

Breaking Medicine News(10 mins):Health News:ONE and Malaria No More Launch 'Malaria Griots' 2 Health News:ONE and Malaria No More Launch 'Malaria Griots' 3 Health News:ONE and Malaria No More Launch 'Malaria Griots' 4 Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 2 Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 3 Health News:Immune cell activity linked to worsening COPD 2 Health News:Immune cell activity linked to worsening COPD 3 Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 2 Health News:Breast Growth in Boys Might Be Linked to Plastics Chemical 3 Health News:Needle Biopsy Works Well in Diagnosing Breast Cancer 2

[0] ONE and Malaria No More Launch 'Malaria Griots'[1] Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference [1] Immune cell activity linked to worsening COPD [0] Breast Growth in Boys Might Be Linked to Plastics Chemical [0] Needle Biopsy Works Well in Diagnosing Breast Cancer

... who have had vaginal deliveries prior to their menopause share ... sisters who have never given birth // . In other ... their counterparts. ,Over 10 million people worldwide are ... other. It is a major health issue that consumes ...

... new study conducted by University of Michigan researchers says that ... The researchers arrived //at this conclusion after tracking 490 heart ... attack or severe chest pain. ,All these patients ... all the medical data about themselves plus gave the limit ...

... an alarming increase in the number of HIV/AIDS cases. The State ... HIV cases has gone beyond 8,500. The percentage of increase registered ... while it was only at 0.39% in 2003, according to West ... home to about 5.1 million HIV/AIDS patients. West Bengal is witnessing ...

Fatehpur Sikri, Mughal Emperor Akbar's dream city, has come up some new finds, thanks to the labourious// excavatory work of the Archaeological Survey of India (ASI). ,According to Munazar Ali, a mo...

... to occur in the case of young women who smoke, ... or start smoking later in life // . The researchers ... Women who start smoking before their first pregnancy stand a ... women who started smoking after the birth of the first ...

... form an integral part of a healthy diet. But with ... untreated juice. Consumers today have numerous choices when it comes ... is whether juices have undergone safety treatments from microbes. ... diarrhoeal illness due to juice have been reported. Some ...

Other Medicine News:Health News:Urinary Stress Incontinence Not Related To Childbirth 2

Urinary Stress Incontinence Not Related To Childbirth Fairer Sex Better Equipped To Deal With Heart Disease WBSACS Says Number Of AIDS Cases On The Rise Mughal era 'Hamams' and hospital discovered at Fatehpur Sikri Women Who Smoke Are More Likely To Get Breast Cancer Unpasteurised juices found to be potential health hazards

(Date:12/15/2009)... -- Today,s New York Times ... Drugs Spurs Division," illustrates an internal renal community ... continuing to be deprived of their life-saving immunosuppressive ... ,, As Congress is poised to approve this ... of transplant kidney recipients, behind-the-scenes debate continues within ...

(Date:12/15/2009)... 15 Reportlinker.com announces that ... available in its catalogue: ,, ... Analysis and Market Forecasts to 2015 ... ,, Systemic Lupus Erythematosus - Drug ... 2015 ,, Summary ,, ...

(Date:12/15/2009)... Dec. 15 Reportlinker.com announces ... is available in its catalogue: ,, ... - Market Forecasts to 2015, Competitive ... ,, http://www.reportlinker.com/p0168102/The-Future-of-HIV-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, ... has released its latest research "The ...

[0] AST Concerned That Kidney Transplant Patients May Suffer Politics As Usual in Capitol Hill Health Care Reform Debate [0] Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 [0] Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

... Iceland, Oct. 9 deCODE genetics,(Nasdaq: DCGN ... patients for its,Phase IIa clinical trial for DG051, ... the prevention of heart attack. In Phase ... the production of leukotriene B4 (LTB4) in a ...

... Oct. 8 Oculus Innovative,Sciences, Inc. (Nasdaq: OCLS ... the 4th Annual BIO InvestorForum Conference to be held,October ... The company,s,president and chief executive officer, Hoji Alimi, is ... programs and the most recent,quarter on Thursday, October 11 ...

Other Medicine Technology:deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack 2 deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack 3 Oculus Innovative Sciences to Present at 4th Annual BIO InvestorForum Conference 2

deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack Oculus Innovative Sciences to Present at 4th Annual BIO InvestorForum Conference

... special order products are offered as 1-piece ... lengths. The modular instruments may be customized ... such as ratchets, insulation and flush ports. ... stock. Customer specifications may affect delivery times. ...

... offered as 1-piece or modular, in regular ... may be customized with handles of choice ... and flush ports. Many standard patterns are ... affect delivery times. , Please Note: ...

... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...

Medicine Products:

Dissecting Forceps Atraumatic Endo- Clinch Grasper Pointed Biopsy Grasping Forceps Long Jaw Maxi-Grasper

Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Qu...(accompanying table entitled Reconciliat...),Health